Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

ClinicalTrials.gov ID: NCT00677807

Public ClinicalTrials.gov record NCT00677807. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 9:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 26-week Extension to a 26-week Treatment, Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptive, Seamless, Parallel-group Study to Assess Safety, Tolerability and Efficacy of Two Doses of Indacaterol (150 and 300 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study evaluated the 1 year safety, tolerability and efficacy of indacaterol against placebo in the treatment of Chronic Obstructive Pulmonary Disease (COPD) patients

Study identification

NCT ID
NCT00677807
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis
Industry
Enrollment
415 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2008
Primary completion
Feb 28, 2009
Completion
Feb 28, 2009
Last update posted
Aug 21, 2011

2008 – 2009

United States locations

U.S. sites
93
U.S. states
35
U.S. cities
86
Facility City State ZIP Site status
Novartis Investigative Site Homewood Alabama 35209-6870
Novartis Investigative Site Jasper Alabama 35501
Novartis Investigative Site Phoenix Arizona 85013
Novartis Investigative Site Tucson Arizona 85712
Novartis Investigative Site Pine Bluff Arkansas 71603
Novartis Investigative Site Encinitas California 92024-1332
Novartis Investigative SIte Fullerton California 92835
Novartis Investigative Site Orange California 92869
Novartis Investigative Site Riverside California 92506
Novartis Investigative Site Spring Valley California 91978
Novartis Investigative site Fort Collins Colorado 80528
Novartis Investigative site Golden Colorado 80401
Novartis Investigative Site Wheat Ridge Colorado 80033
Novartis Investigative Site Clearwater Florida 33765
Novartis Investigative Site Largo Florida 33770
Novartis Investigative Site Pensacola Florida 32504
Novartis Investigative Site Rockledge Florida 32955
Novartis Investigative Site South Miami Florida 33143
Novartis Investigative Site Tamarac Florida 33321
Novartis Investigative Site Tampa Florida 33603
Novartis Investigative Site Atlanta Georgia 30342
Novartis Investigative Site Marietta Georgia 30060
Novartis Investigative Site Normal Illinois 61761
Novartis Investigative Site O'Fallon Illinois 62269
Novartis Investigative Site River Forest Illinois 60305
Novartis Investigative Site Indianapolis Indiana 46256
Novartis Investigative Site Iowa City Iowa 52240
Novartis Investigative Site Iowa City Iowa 52242
Novartis Investigative Site Topeka Kansas 66606
Novartis Investigative Site Crescent Springs Kentucky 41017
Novartis Investigative Site Lexington Kentucky 40504
Novartis Investigative Site Lexington Kentucky 40536
Novartis Investigative Site Lafayette Louisiana 70503
Novartis Investigative Site Metaire Louisiana 70002
Novartis Investigative site New Orleans Louisiana 70112
Novartis Investigative Site Biddeford Maine 04005
Novartis Investgative Site Clarkston Michigan 48346
Novartis Investigative Site Flint Michigan 48532
Novartis Investigative Site Livonia Michigan 48152
Novartis Investigative site Troy Michigan 48085
Novartis Investigative Site Minneapolis Minnesota 55402
Novartis Investigative Site Minneapolis Minnesota 55407
Novartis Investigative Site Rochester Minnesota 55905
Novartis Investigative Site Chesterfield Missouri 63017
Novartis Investigative Site Columbia Missouri 65212
Novartis Investigative Site Kansas City Missouri 64108-2677
Novartis Investigative Site St Louis Missouri 63141
Novartis Investigative Site Billings Montana 59102
Novartis Investigative Site Kalispell Montana 59901
Novartis Investigative Site Lincoln Nebraska 68510
Novartis Investigative Site Omaha Nebraska 68130
Novartis Investigative Site Omaha Nebraska 68134
Novartis Investigative Site Omaha Nebraska 68198-5885
Novartis Investigative Site Papillion Nebraska 68046
Novartis Investigative site Henderson Nevada 89014
Novartis Investigative site Summit New Jersey 07901
Novartis Investigative Site Elmira New York 14905
Novartis Investigative site New York New York 10016
Novartis Investigative Site Rochester New York 14618-2638
Novartis Investigative Site Charlotte North Carolina 28207
Novartis Investigative Site Shelby North Carolina 28150
Novartis Investigative Site Winston-Salem North Carolina 27103
Novartis Investigative Site Fargo North Dakota 58122
Novartis Investigative Site Cincinnati Ohio 45245
Novartis Investigative Site Cleveland Ohio 44109-1998
Novartis Investigative Site Columbus Ohio 43213
Novartis Investigative Site Columbus Ohio 43215
Novartis Investigative Site Marion Ohio 43302
Novartis Investigative Site Sylvania Ohio 43650
Novartis Investigative Site Thornville Ohio 43076
Novartis Investigative Site Zanesville Ohio 43701
Novartis Investigative Site Oklahoma City Oklahoma 73104
Novartis Investigative Site Tulsa Oklahoma 74135-2920
Novartis Investigative Site Eugene Oregon 97404-3233
Novartis Investigative Site Medford Oregon 97504-8741
Novartis Investigative Site Erie Pennsylvania 16506
Novartis Investigative Site Pittsburgh Pennsylvania 15221
Novartis Investigative Site Pittsburgh Pennsylvania 15243
Novartis Investigative site Cranston Rhode Island 02920
Novartis Investigative Site Cumberland Rhode Island 02864
Novartis Investigative Site Greenville South Carolina 29615
Novartis Investigative Site Johnson City Tennessee 37601
Novartis Investigative Site Corsicana Texas 75110
Novartis Investigative Site Dallas Texas 75231
Novartis Investigative site El Paso Texas 79902
Novartis Investigative Site Fort Worth Texas 76104
Novartis Investigative Site San Antonio Texas 78229
Novartis Investigative Site Abingdon Virginia 24210
Novartis Investigative site Lynchburg Virginia 24501
Novartis Investigative Site Richmond Virginia 23249
Novartis Investigative Site Bellingham Washington 98225
Novartis Investigative site Spokane Washington 99216
Novartis Investigative Site Milwaukee Wisconsin 53209-0996

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 97 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00677807, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 21, 2011 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00677807 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →